Muhammad Waqas Sadiq
AstraZeneca (Sweden)(SE)
Publications by Year
Research Areas
Asthma and respiratory diseases, Inhalation and Respiratory Drug Delivery, Pharmacological Effects and Toxicity Studies, IL-33, ST2, and ILC Pathways, Epilepsy research and treatment
Most-Cited Works
- → Biocompatible, Purified VEGF-A mRNA Improves Cardiac Function after Intracardiac Injection 1 Week Post-myocardial Infarction in Swine(2018)168 cited
- → Diphenhydramine Active Uptake at the Blood–Brain Barrier and Its Interaction with Oxycodone in vitro and in Vivo(2011)107 cited
- → A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection(2016)43 cited
- → A Randomized Phase I Study of the Anti‐Interleukin‐33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease(2023)38 cited
- → Validation of a P-Glycoprotein (P-gp) Humanized Mouse Model by Integrating Selective Absolute Quantification of Human MDR1, Mouse Mdr1a and Mdr1b Protein Expressions with In Vivo Functional Analysis for Blood-Brain Barrier Transport(2015)35 cited
- → Oxymorphone Active Uptake at the Blood–Brain Barrier and Population Modeling of its Pharmacokinetic–Pharmacodynamic Relationship(2013)33 cited
- → Lung pharmacokinetics of inhaled and systemic drugs: A clinical evaluation(2021)33 cited
- → Prediction of lisinopril pediatric dose from the reference adult dose by employing a physiologically based pharmacokinetic model(2020)14 cited
- → Morphine Brain Pharmacokinetics at Very Low Concentrations Studied with Accelerator Mass Spectrometry and Liquid Chromatography-Tandem Mass Spectrometry(2010)13 cited
- → Characterisation of pharmacokinetics, safety and tolerability in a first‐in‐human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory disease(2021)13 cited